Table 1.
Summary of prevalence results (%) from fitted models (youths ⩽18 years and adults >18 years)
| Covariate | Model 1: All data | Model 2: Diagnostic interview subset |
|---|---|---|
| Gender × Age group × Diagnostic method | ||
| F, Adult, Interview (n = 3) | 17.8 | n.a. |
| F, Adult, Screen (n = 5) | 37.8 | |
| F, Child/Adolescent, Interview (n = 5) | 31.3 | |
| F, Child/Adolescent, Screen (n = 2) | 66.5 | |
| M, Adult, Interview (n = 9) | 25.3 | |
| M, Adult, Screen (n = 19) | 30.7 | |
| M, Child/Adolescent, Interview (n = 13) | 30.0 | |
| M, Child/Adolescent, Screen (n = 5) | 45.6 | |
| p value | 0.006 | |
| Gender × Age group | ||
| F, Adult (n = 3) | n.a. | 22.1 |
| F, Child/Adolescent (n = 5) | 30.8 | |
| M, Adult (n = 9) | 31.2 | |
| M, Child/Adolescent (n = 13) | 29.5 | |
| p value | 0.242 | |
| Study design (n1 = 61, n2 = 30) | ||
| Current diagnoses | 23.4 | 21.7 |
| Retrospective child diagnoses | 47.1 | 36.4 |
| p value | <0.0001 | <0.001 |
| Country a | ||
| Austria (n1 = 2, n2 = 2) | 60.7 | 47.8 |
| Brazil (n1 = 2, n2 = 2) | 9.4 | 6.6 |
| Canada (n1 = 1, n2 = 0) | 49.1 | |
| Germany (n1 = 5, n2 = 2) | 49.3 | 31.4 |
| Greece (n1 = 1, n2 = 0) | 45.6 | |
| Iceland (n1 = 4, n2 = 0) | 39.2 | |
| Iran (n1 = 1, n2 = 1) | 51.0 | 40.1 |
| Ireland (n1 = 1, n2 = 0) | 13.4 | |
| South Korea (n1 = 2, n2 = 0) | 35.5 | |
| Netherlands (n1 = 2, n2 = 2) | 18.0 | 14.2 |
| Nigeria (n1 = 1, n2 = 1) | 22.8 | 18.1 |
| Spain (n1 = 3, n2 = 1) | 50.4 | 45.5 |
| Sweden (n1 = 8, n2 = 1) | 50.1 | 65.2 |
| UK (n1 = 4, n2 = 1) | 31.4 | 39.4 |
| USA (n1 = 24, n2 = 17) | 33.8 | 25.7 |
| p value | <0.002 | <0.0001 |
F, Female; M, male; n.a., not applicable.
a
The number of study strata included are listed in parentheses for each covariate (number of strata in models 1 and 2 are provided for covariates in both models, respectively). The numbers of studies in each country are: Austria (n = 1), Brazil (n = 1), Canada (n = 1), Germany (n = 3), Greece (n = 1), Iceland (n = 2), Iran (n = 1), Ireland (n = 1), South Korea (n = 1), Netherlands (n = 2), Nigeria (n = 1), Spain (n = 2), Sweden (n = 6), UK (n = 3), USA (n = 16). All studies are listed in Supplementary Tables S1 and S2.